Technology platforms and capabilities

Scientist at Hudson Institute working in the technology platforms and capabilities facility.

Our pursuit of excellence is underpinned by world-leading capabilities and expertise through our integrated network of Technology Platforms.

To achieve the highest level of quality, the MHTP Partners have made significant investments in our technology capabilities that operate within a unified strategy, governance and quality framework. Several technology platforms have already achieved NATA accredited promoting shared research and clinical utilisation. Access is available via a collaborative or fee-for-service model throughout the MHTP as well as to national scientific communities.

Creating seamless interaction between use of technology platforms, research and clinical trials capabilities, our Technology Platforms are co-located on a central floor within our new $84M Translational Research Facility (TRF). This not only makes them easily accessible, but also enables innovative approaches to research that integrate knowledge generated from multiple state-of-the-art technologies.

RNAte Technology Platform

The RNAte platform is designed to address the need for testing the immunoreactivity of RNA-based products, especially in established human cell models. The platform places a high priority on human induced pluripotent stem cell (iPSC) models for sensitive and accurate detection of immune responses.

Leveraging robotic automation in testing services enables high throughput applications for library screening or testing of different conditions, thereby aiding the optimisation of new product development. Using iPSC models can reduce the risk of clinical trials failure and has the potential to accelerate the development of new RNA and mRNA products in the manufacturing pipeline.

View more information here, or visit our website http://rnate.com.au


General enquiries | enquiry@rnate.com.au

Dr Esther Ling | Facility Manager
RNAte Technology Platform
Hudson Institute of Medical Research | Translational Research Facility
t: +61 3 8572 2770
e: esther.ling@rnate.com.au

Dr Sarah Straub | Development Scientist
RNAte Technology Platform
Hudson Institute of Medical Research | Translational Research Facility
t: +61 3 8572 2459
e: sarah.straub@rnate.com.au

Hudson Cell Therapies

Hudson Cell Therapies

Hudson Cell Therapies provides a facility for the safe, efficient and rapid manufacturing of human blood and tissue products.

Hudson Cell Therapies allows clinicians based in the Monash Medical Precinct and elsewhere to have blood products processed outside the Melbourne CBD for the first time, improving accessibility for clinical trials.

Operating within a PC2 & ISO 8 certified clean room facility and housing a cryopreservation suite operated to ISO 15189 standards, Hudson Cell Therapies is qualified to receive, store and distribute human cellular therapy products in support of multi-site clinical cell therapy trials.

 View more information here


General enquiries | hudson-ct@hudson.org.au

Dr Gordon McPhee | Facility Manager
Hudson Cell Therapies
Hudson Institute of Medical Research | Translational Research Facility

Dr Mirja Krause | Quality Manager
Hudson Cell Therapies

Flow cytometry

Histology

Genomics

Micro imaging

Proteomics

Support life saving scientific discoveries

DONATE NOW